[Analysis of Neoadjuvant Chemotherapy for HER2-Positive Breast Cancer in Our Department]

We investigated neoadjuvant chemotherapy for patients with human epidermal growth factor receptor 2(HER2)-positive breast cancer. Twenty-eight patients with HER2-positive breast cancer received neoadjuvant chemotherapy from January 2011 to December 2017. Of the 28 patients, pathological complete response(pCR)was achieved in 14 patients. The pCR rate for the docetaxel(DTX)-containing regimen was 47.4%, whereas that for the nanoparticle albumin-bound paclitaxel(nab- PTX)-containing regimen was 71.4%. Therefore, nab-PTX-containing therapy may be more effective than a DTX-containing regimen for patients with HER2-positive breast cancer.